Chinese biotech skincare company specializing in recombinant collagen skincare and medical dressing products, under the Kefumei brand.
Chinese biotech skincare company specializing in recombinant collagen skincare and medical dressing products, under the Kefumei brand.
Sells mostly through online storefronts, driven by heavy spending on livestream and social-media marketing, with the Kefumei brand carrying most revenue and the products positioned as medical-grade rather than ordinary cosmetics. Founder Fan Daidi, a university professor, leads the company.
In one line: A Chinese bio-skincare innovator.
Moat: narrow (IP / patents, brand). Proprietary recombinant collagen technology and patents differentiate it from conventional skincare brands.
Headquarters: Jinan, Shandong, China · Founded: 2000 · Employees: 2,201
Size Giant Biogene (2367.HK) is a Hong Kong Consumer Staples company (Household/Personal Care) with a market value of $2.47B, the 364th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$19.13 on 18 Nov 2026.
Performance Over six months the shares fell 31.7%, against +7.1% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue fell 9.7% over the last twelve months (peer median +2.3%); the operating margin is 31.7% (peer median 10.6%).
Valuation It trades at 8.6× forward earnings against a peer median of 23.2× (cheapest of 21).
Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +35%, so the hurdle is -46 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 58.4 points above its cost of capital (9.8% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$5.96B | HK$5.98B | HK$6.01B | HK$3.89B | HK$2.75B |
| Revenue growth | — | 0% | +54% | +42% | — |
| Gross profit | HK$4.71B | HK$4.81B | HK$4.93B | HK$3.26B | HK$2.32B |
| EBITDA | HK$1.99B | HK$2.39B | HK$2.53B | HK$1.82B | HK$1.35B |
| Net income | HK$1.87B | HK$2.08B | HK$2.24B | HK$1.60B | HK$1.17B |
| Free cash flow | HK$2.05B | HK$1.65B | HK$2.07B | HK$1.62B | HK$921M |
| Capital expenditure | HK$293M | HK$480M | HK$268M | HK$252M | HK$178M |
| Total debt | n/a | HK$10.8M | HK$7.14M | HK$3.00M | HK$2.90M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Giant Biogene 2367.HK | $2.47B | -32% | -10% | 32% | 8.6× | -10.7% |
| Mao Geping Cosmetics 1318.HK | $4.67B | -8% | +32% | 31% | 14.3× | 4.1% |
| Bloomage Biotechnology 688363.SS | $2.27B | -21% | -22% | 5% | 52.0× | 19.0% |
| Proya Cosmetics 603605.SS | $2.87B | -13% | +2% | 13% | 10.9× | -5.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2367.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.8% | +3.5% | 2nd lowest of 21 |
| 6-month return | -31.7% | +7.1% | 2nd lowest of 21 |
| Distance from 52-week high | -53.7% | -22.4% | lowest of 21 |
| Revenue growth (TTM) | -9.7% | +2.3% | lowest of 21 |
| Operating margin | 31.7% | 10.6% | highest of 21 |
| Forward P/E | 8.6× | 23.2× | cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | -10.7% | 0.5% | least demanding of 17 |
| Growth delivered (Del g) | +34.9% | +5.1% | highest of 17 |
| Hurdle (Req g minus delivered) | -45.6 pp | -3.3 pp | least demanding of 17 |
| ROIC minus cost of capital | +58.4 pp | +5.1 pp | 2nd highest of 20 |
| EV / EBITDA | 5.4× | 12.3× | cheapest of 16 |
| Net debt / EBITDA | -4.3× | -0.6× | 2nd least indebted of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Giant Biogene 2367.HK | Hong Kong | $2.47B | -32% | -10% | 32% | 8.6× | -10.7% | +34.9% |
| Cosmax 192820.KS | South Korea | $2.51B | +53% | +25% | 8% | 18.8× | n/a | n/a |
| Winner Medical 300888.SZ | China | $2.53B | -6% | +4% | 11% | 19.9× | -5.2% | -2.6% |
| Gillette India GILLETTE.NS | India | $2.53B | -5% | +8% | 28% | 37.1× | 14.9% | +13.0% |
| Procter & Gamble Hygiene & Health Care PGHH.NS | India | $2.37B | -30% | -2% | 24% | 27.0× | 21.2% | +7.4% |
| Softcare 2698.HK | Hong Kong | $2.20B | +5% | +25% | 25% | 14.4× | 9.1% | +20.9% |
| LG H&h 051900.KS | South Korea | $2.81B | -14% | -3% | 3% | 23.1× | -4.6% | -4.1% |
| KOSE 4922.T | Japan | $2.16B | +16% | +4% | 5% | 29.9× | n/a | n/a |
| Proya Cosmetics 603605.SS | China | $2.87B | -13% | +2% | 13% | 10.9× | -5.3% | +23.1% |
| Blue Moon 6993.HK | Hong Kong | $2.07B | -4% | -2% | -2% | 103.3× | n/a | n/a |
| Kolmar Korea 161890.KS | South Korea | $2.05B | +14% | +16% | 10% | 14.3× | -1.6% | +15.5% |
| Pola Orbis 4927.T | Japan | $2.04B | +15% | +1% | 11% | 30.6× | -2.0% | -0.7% |
| Emami EMAMILTD.NS | India | $1.94B | -5% | +13% | 20% | 23.4× | 21.5% | +5.6% |
| Energizer ENR | United States | $1.94B | +71% | 0% | 17% | 9.1× | -5.1% | -0.5% |
| Kobayashi Pharmaceutical 4967.T | Japan | $3.25B | +20% | +2% | 6% | 48.7× | 18.0% | +1.9% |
| Hengan Int'l 1044.HK | Hong Kong | $3.27B | -12% | +2% | 11% | 9.1× | -8.2% | -0.1% |
| Pigeon 7956.T | Japan | $1.76B | +26% | +8% | 13% | 27.9× | -2.4% | +1.9% |
| Interparfums ITP.PA | France | $3.49B | +66% | -4% | 18% | 26.9× | 15.6% | +19.6% |
| Yunnan Botanee Bio-Technology 300957.SZ | China | $1.69B | -33% | +7% | 9% | 19.1× | 2.6% | +15.3% |
| Coty COTY | United States | $3.71B | +116% | 0% | 5% | 13.5× | 9.8% | +4.6% |
| Guangdong Marubi Biotechnology 603983.SS | China | $1.62B | +9% | -6% | 2% | 45.5× | n/a | n/a |